98%
921
2 minutes
20
The aim of this study was to show a case of a Class III subdivision adult patient treated with clear aligners (CA) and the extraction of a lower bicuspid. A 19-year-old male with a class III canine and molar relationship on the right side and a deviation of lower dental midline to the left asked for an aesthetic treatment. He refused orthognathic surgical procedures, so he was offered a camouflage orthodontic treatment with the extraction of lower right first premolar to achieve a canine Class I relationship and to center the lower midline. The treatment was performed with clear aligners and the use of Class III elastics to maintain distal anchorage on the right side during the canine distalization. At the end of the treatment, the occlusal objectives were achieved.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967822 | PMC |
http://dx.doi.org/10.3390/ijerph20043550 | DOI Listing |
JAMIA Open
October 2025
Fetal-Neonatal Neuroimaging Developmental Science Center, Division of Newborn Medicine, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, United States.
Objectives: To develop a data harmonization framework for neonatal hypoxic-ischemic encephalopathy (HIE) studies and demonstrate its suitability for prognostic biomarker development.
Materials And Methods: Variables were first categorized by chronological stages and then by medical topics. We created a dictionary to harmonize variable names and value coding.
J Metab Bariatr Surg
August 2025
Office of Medical Education, Seoul National University College of Medicine, Seoul, Korea.
Obesity represents a major global health challenge, requiring interventions that are both effective and economically sustainable. This review examines the cost-effectiveness of commonly discussed treatment options: glucagon-like peptide-1 receptor agonists (GLP-1 RAs), endoscopic sleeve gastroplasty (ESG), and metabolic/bariatric surgery (MBS). We synthesized evidence from published clinical studies and economic analyses, comparing incremental cost-effectiveness ratios (ICERs) and cost per quality-adjusted life year across obesity severity classes, with particular consideration of implications for Korea's healthcare context.
View Article and Find Full Text PDFHeart Rhythm O2
August 2025
Hospital Privado del Sur & Hospital Regional Español, Bahía Blanca, Argentina.
Background: Patient characteristics and outcomes of newly diagnosed atrial fibrillation (AF) have been investigated in large registries.
Objective: The study aimed to address the role of non-invasive screening tools in diagnosing AF in the Argentinian clinical practice.
Methods: This was an observational retrospective study.
Eur J Heart Fail
September 2025
School of Cardiovascular & Metabolic Medicine and Science, James Black Centre, King's College London British Heart Foundation Centre of Excellence, London, UK.
Aims: Skeletal muscle energetic augmentation might be a mechanism via which intravenous iron improves symptoms in heart failure, but no direct measurement of intrinsic mitochondrial function has been performed to support this notion. This molecular substudy of the FERRIC-HF II trial tested the hypothesis that ferric derisomaltose (FDI) would improve electron transport chain activity, given its high dependence on iron-sulfur clusters which facilitate electron transfer during oxidative phosphorylation.
Methods And Results: Vastus lateralis skeletal muscle biopsies were taken before and 2 weeks after randomization.
Eur J Heart Fail
September 2025
Brazilian Clinical Research Institute (BCRI), São Paulo, Brazil.
Aims: The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC). We describe the baseline characteristics of participants in PARACHUTE-HF compared with prior HFrEF trials.
Methods And Results: PARACHUTE-HF, a multicentre, active-controlled, open-label trial, enrolled 922 participants with confirmed CCC, New York Heart Association (NYHA) functional class II-IV, and left ventricular ejection fraction (LVEF) ≤40%.